EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Derivatives of MOPS : promising scaffolds for SARS coronaviruses Macro domain‐targeted inhibition

Oney Ortega Granda, Karine Alvarez, Benjamin Morin, Bruno Canard, François Ferron iD, Nadia Rabah iD

The FEBS Journal · 2025

DOI: 10.1111/febs.70039 ↗

At a glance

Journal article in The FEBS Journal, 2025. Written by Oney Ortega Granda and 5 co-authors. Institution: Aix Marseille Université, CNRS, AFMB UMR 7257, Marseille, France. Major MEDLINE topics: SARS-CoV-2, Viral Nonstructural Proteins, Antiviral Agents. 71 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: French Infrastructure for Integrated Structural Biology, European Synchrotron Radiation Facility, Innovative Medicines Initiative 2 Joint Undertaking (JU).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The severe acute respiratory syndrome coronavirus (SARS‐CoV/CoV‐2) genome encodes 16 non‐structural proteins (nsps), which coordinate cell remodeling, virus replication and participate in viral evasion. Notably, nsp3 contains a protein module termed Macro domain, which carries IFN antagonist activity that interferes with host innate immunity response. This domain is able to bind and hydrolyze ADP‐ribose derivatives. This activity is correlated to viral escape and thus makes Macro domains a valuable therapeutic target. In the present paper, we report a SARS‐CoV Macro domain structure in complex with a MOPS molecule. Based on our structural data, molecular docking was performed on a set of MOPS analogs in the ADP‐ribose binding pocket. We present an ELISA‐based assay to select hits based on the inhibition of recombinant SARS‐CoV/CoV‐2 Macro domain‐ADP‐ribose complex formation. Among the tested analogs, MOPSO and CAPSO are the more efficient in inhibiting ADP‐ribose‐binding. Structural analysis of these molecules in the ADP‐ribose pocket reveals potential interactions with amino acid residues involved in the coordination of ADP‐ribose. Overall, these findings suggest that MOPSO and CAPSO bear potential to be used as a scaffold for the design of Macro domain‐specific inhibitors.

Subjects

MeSH terms (MEDLINE)

SARS-CoV-2Viral Nonstructural ProteinsAntiviral AgentsHumansMolecular Docking SimulationAdenosine Diphosphate RiboseProtein DomainsBinding SitesProtein BindingCOVID-19COVID-19 Drug Treatment

Author keywords

ELISA‐like screeningMOPS analogsSARS‐CoV/CoV‐2macro domaintherapeutic target

Substances

Adenosine Diphosphate RiboseViral Nonstructural ProteinsAntiviral Agents

Authors and institutions

  • Aix Marseille Université, CNRS, AFMB UMR 7257, Marseille, France.
  • European Virus Bioinformatics Center, Jena, Germany.

ORCID profiles: François Ferron, Nadia Rabah

Funding

  • French Infrastructure for Integrated Structural Biology
  • European Synchrotron Radiation Facility
  • Innovative Medicines Initiative 2 Joint Undertaking (JU)
  • Initiative d'Excellence d'Aix-Marseille Université

Cite

APA

Ortega Granda, O., Alvarez, K., Morin, B., Canard, B., Ferron, F., & Rabah, N. (2025). Derivatives of MOPS : promising scaffolds for SARS coronaviruses Macro domain‐targeted inhibition. The FEBS Journal. https://doi.org/10.1111/febs.70039

Vancouver

Ortega Granda O, Alvarez K, Morin B, Canard B, Ferron F, Rabah N. Derivatives of MOPS : promising scaffolds for SARS coronaviruses Macro domain‐targeted inhibition. The FEBS Journal. 2025. doi:10.1111/febs.70039

BibTeX
@article{OrtegaGranda2025,
  author = {Ortega Granda, Oney and Alvarez, Karine and Morin, Benjamin and Canard, Bruno and Ferron, François and Rabah, Nadia},
  title = {Derivatives of MOPS : promising scaffolds for SARS coronaviruses Macro domain‐targeted inhibition},
  journal = {The FEBS Journal},
  year = {2025},
  doi = {10.1111/febs.70039}
}
Start for free →